LSN 3321213
Alternative Names: LSN-3321213Latest Information Update: 12 Jan 2024
Price :
$50 *
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics
- Mechanism of Action Aurora kinase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Non small cell lung cancer presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
- 14 Apr 2023 Preclinical trials in Non-small cell lung cancer in USA (unspecified route), prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Non small cell lung cancer presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)